Mentioned:
Novo Nordisk is ramping up their commitment to artificial intelligence. And now, they’ve just formed a new collaboration with Anthropic.
What’s happening:
- Novo Nordisk (NYSE: NVO) has struck a new partnership with Anthropic to begin using their Claude family of artificial intelligence models for drug discovery and internal software development
Why it matters:
- Novo Nordisk has publicly stated they will test Claude Science on highly specific research and development workflows as well as to target complex problems that have been identified by scientists at Novo Nordisk
Going deeper:
- This is the first time that Novo Nordisk has formed a partnership with Anthropic company to integrate their technology into drug discovery workflows
- Novo Nordisk has previously cut a deal with OpenAI to use their artificial intelligence models in scientific research as well as commercial operations and Nvidia (NASDAQ: NVDA) to use Denmark’s Gefion supercomputer to create customized artificial intelligence models for early research and clinical development
The intrigue:
- Anthropic has been striking a flurry of deals with public traded companies lately, including committing to deploy 2 gigawatts of AMD’s (NASDAQ: AMD) newest artificial intelligence chips and GPUS and locking in a 20 year lease with TeraWulf (NASDAQ: WULF) for data centre capacity in Kentucky
